Ot­su­ka gob­bles up more glob­al rights for Ake­bia’s vadadu­s­tat, chip­ping in to a pot now worth $2B-plus

Late last year Ot­su­ka stepped in with a deal worth more than a bil­lion dol­lars to part­ner with Ake­bia on its ex­per­i­men­tal ane­mia drug vadadu­s­tat in the US mar­ket. But the pact ev­i­dent­ly on­ly whet­ted its ap­petite for more.

In a deal ex­ten­sion an­nounced af­ter the mar­ket closed on Tues­day, Ot­su­ka came back to grab Eu­rope, Chi­na, Rus­sia and much of the rest of the world, pay­ing an­oth­er $208 mil­lion in com­mit­ted cap­i­tal cov­er­ing $73 mil­lion up­front and $135 mil­lion to cov­er de­vel­op­ment costs. There’s al­so $657 mil­lion in po­ten­tial mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.